At 11.0% CAGR, Middle East & Africa Bioproduction Market is Projected to be Worth US$ 652.96 Million by 2030, says Business Market Insights

According to Business Market Insights' research, the Middle East & Africa bioproduction market was valued at US$ 283.68 million in 2022 and is expected to reach US$ 652.96 million by 2030, registering a CAGR of 11.0% from 2022 to 2030. Rising adoption of regenerative medicines and increasing prevalence of chronic diseases are among the critical factors attributed to drive the Middle East & Africa bioproduction market growth.

Regenerative therapies help in the regeneration of cells, tissues, and organs to restore their functions. A number of regenerative medicine applications for human clinical trials are submitted to the Food and Drug Administration (FDA) each year. As per the Alliance for Regenerative Medicine, in 2019 (Q3), 1,052 clinical trials utilizing regenerative medicine were underway globally; 218 cellular therapy trials were underway (41 Phase I, 147 Phase II, 30 Phase III) in 2019. Rapid advancements are being made in regenerative medicines to provide effective solutions for chronic conditions. Cell therapy is one of the fastest-growing segments of the regenerative medicine domain. Novartis' Kymriah was the first cell therapy solution offered to treat B-cell acute leukemia. Moreover, RepliCel, a regenerative medicine provider, has a wide range of regenerative medicine products in the pipeline, with three products-RCH-01, RCS-01, and RCT-01-in the development phase. Further, Sernova is engaged in the development of regenerative medicine technologies and has a huge pipeline of products for conditions such as diabetes, hemophilia A, and hyperthyroidism. Thus, the rising adoption of regenerative medicines is driving the bioproduction market.

On the contrary, high cost of cell therapy and biosimilar manufacturing hampers the growth of Middle East & Africa bioproduction market.

Based on product, the Middle East & Africa bioproduction market is segmented into biologics and biosimilars, vaccines, cell and gene therapies, nucleic acid therapeutics, and others. The biologics and biosimilars segment held 37.6% Middle East & Africa bioproduction market share in 2022, amassing US$ 106.57 million. It is projected to garner US$ 229.59 million by 2030 to register 10.1% CAGR during 2022-2030.

In terms of application, the Middle East & Africa bioproduction market is segmented into rheumatoid arthritis, hematological disorders, cancer, diabetes, cardiovascular diseases, and others. The cancer segment held 37.6% share of Middle East & Africa bioproduction market in 2022, amassing US$ 106.70 million. It is anticipated to garner US$ 255.56 million by 2030 to expand at 11.5% CAGR during 2022-2030.

By equipment, the Middle East & Africa bioproduction market is divided into upstream equipment, downstream equipment, bioreactors, and consumables and accessories. The consumables and accessories segment held 39.3% share of Middle East & Africa bioproduction market in 2022, amassing US$ 111.62 million. It is projected to garner US$ 271.66 million by 2030 to expand at 11.8% CAGR from 2022 to 2030.

In terms of end user, the Middle East & Africa bioproduction market is categorized into biopharmaceutical companies, contract manufacturing organizations, and others. The biopharmaceutical companies segment held 52.9% share of Middle East & Africa bioproduction market in 2022, amassing US$ 150.08 million. It is projected to garner US$ 341.90 million by 2030 to expand at 10.8% CAGR from 2022 to 2030.

Based on country, the Middle East & Africa bioproduction market is categorized into Saudi Arabia, the UAE, South Africa, and the Rest of Middle East & Africa. Our regional analysis states that Saudi Arabia captured 39.9% share of Middle East & Africa bioproduction market in 2022. It was assessed at US$ 113.13 million in 2022 and is likely to hit US$ 268.76 million by 2030, registering a CAGR of 11.4% during 2022-2030.

Key players operating in the Middle East & Africa bioproduction market are Lonza Group AG, Danaher Corp, Sartorius AG, Thermo Fisher Scientific Inc, Merck KGaA, F. Hoffmann-La Roche Ltd, and Bio-Rad Laboratories Inc., among others.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com